Molecular Profile | BRAF G466V |
Therapy | Vemurafenib |
Indication/Tumor Type | colorectal cancer |
Response Type | no benefit |
Create By | spatt |
Update By | spatt |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | BRAF G466V | colorectal cancer | no benefit | Vemurafenib | Preclinical - Pdx | Actionable | In a preclinical study, Zelboraf (vemurafenib) did not inhibit ERK signaling or tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719). | 28783719 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(28783719) | Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. | Full reference... |